Quantcast

Latest Alkaloids Stories

2009-10-01 00:30:00

PHILADELPHIA, Oct. 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that, in a study from Brown University to be presented by Howard Safran, M.D., head of the Brown University Oncology Group, in the proffered oral session at the Annual Meeting of the International Society of Gastrointestinal Oncology (ISGIO) in Philadelphia, Pennsylvania patients with cancer of the lower esophagus demonstrated a high rate of complete remission (CR) when...

2009-09-21 19:00:00

SEATTLE, Sept. 21 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it will re-focus its resources on the approval of OPAXIO(TM) for its potential superiority indication in maintenance therapy for ovarian cancer. The Gynecologic Oncology Group (GOG) is conducting an ongoing phase III trial that evaluates the use of 12 months of OPAXIO therapy versus an untreated control arm. To date, 600 patients have been enrolled in this trial. CTI has...

2009-09-10 07:16:33

Ever wonder why former smokers miss lighting up most when they are in a bar or after a meal with friends? Researchers at Baylor College of Medicine say nicotine, the addictive component in cigarettes, "tricks" the brain into creating memory associations between environmental cues and smoking behavior. The findings appear in the current issue of the journal Neuron. "Our brains normally make these associations between things that support our existence and environmental cues so that we conduct...

2009-09-08 08:40:00

TUSTIN, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported completion of patient enrollment in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients. The trial's planned total of 46 patients has been enrolled and patients are currently undergoing treatment and follow-up. The primary objective of the multi-center, open-label study is to assess the overall tumor...

eee85b9238f9bdda59cc81dc0146b15f1
2009-08-17 16:00:00

Researchers in China have discovered the first protein-based toxin in an amphibian "“a 60 amino acid neurotoxin found in the skin of a Chinese tree frog. This finding may help shed more light into both the evolution of amphibians and the evolution of poison.While gene-encoded protein toxins have been identified in many vertebrate animals, including fish, reptiles and mammals, none have yet been found in amphibians or birds. In the case of poisonous amphibians, like the tropical poison...

2009-08-03 00:30:00

SEATTLE, Aug. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced results from a study released by Dartmouth-Hitchcock Medical Center at the International Association for the Study of Lung Cancer (IASLC) 13th World Conference on Lung Cancer. The study demonstrated that in patients with advanced non-small cell lung cancer (NSCLC), the combination of OPAXIO (paclitaxel poliglumex) and Alimta(R) (pemetrexed) was well tolerated and resulted in median...

2009-07-07 00:30:00

SEATTLE, July 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it had requested and the EMEA has agreed to an oral explanation in support of the OPAXIO Marketing Authorization Application (MAA) in September, 2009 extending the review for the Committee for Medicinal Products for Human Use (CHMP) opinion on approval until Q4-2009. In April, 2008 the EMEA accepted for review the MAA for OPAXIO for first-line treatment of patients with...

2009-07-02 06:30:00

CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel/carboplatin for patients with advanced cancers. The principal investigators for the trial are Dr. Kevin Harrington of The Institute of Cancer Research, London, England, and Dr. Geoff Hall of St. James's Institute of Oncology, Leeds. A total of 30 patients...

2009-06-15 15:57:02

U.S. researchers suggest nicotine may be a reason smoking increases the risk of cardiovascular diseases. Charles Drew University of Medicine and Science in Los Angeles and Western University of Health Sciences in Pomona, Calif., said the studies in animals found nicotine promotes insulin resistance -- a prediabetic condition where blood-sugar levels are above normal. Other studies show people with prediabetes are at greater risk of developing stroke, heart attack and other cardiovascular...

2009-06-11 13:20:40

Researchers have discovered a reason why smoking greatly increases the risk of heart disease and stroke. Nicotine promotes insulin resistance, also called prediabetes, which is a risk factor for cardiovascular disease, according to the new study, which was presented at The Endocrine Society's 91st Annual Meeting in Washington, D.C.Additionally, the study authors were able to partially reverse this harmful effect of nicotine in mice by treating them with the nicotine antagonist mecamylamine, a...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related